Ductal carcinomas of the prostate: A clinicopathological and immunohistochemical study

British Journal of Urology

Volumn 81, Issue 1, 1998, Pages 109-115

  Oxley, I D ^a   Gillatt, O A ^a   MacIver, A G ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Androgen receptor; Carcinoma; Ductal; Prostate

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN; ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; TUMOR MARKER;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; ENZYME ACTIVITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MITOSIS RATE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; TRANSURETHRAL RESECTION; TUMOR DIFFERENTIATION;

ACID PHOSPHATASE; AGED; AGED, 80 AND OVER; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NEOPLASM PROTEINS; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031847094     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1998.00491.x     Document Type: Article

References (19)

1. Melicow MM. Patchter MR. Endometrial carcinoma of prostatic utricle (uterus masculinus). Cancer 1967: 20: 1715-22
2. Young BW. Lagios MD. Endometrial (papillary) carcinoma of the prostatic utricle -response to orchidectomy. Cancer 1973: 32: 1293-301
3. Bostwick DC. Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am }Surg Palhol 1985; 9: 595-609
4. Vale JA. Patel A. Ball AJ. Hendry WF. Chappell ME. Fisher C. Endometrioid carcinoma of the prostate: a misnomer? J R Soc Med 1992: 85: 395-6
5. Millar EKA, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology 1996; 29: 11-9
6. Miyamoto KK, McSherry SA, Dent GA et al Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993: 149: 1015-9
7. Brolin J. Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen. progesterone and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992; 20: 281-95
8. Lee SS. Endometrioid adenocarcinoma of the prostate: a clinicopathologic and immunohistochemical study. J Surg Oncol 1994; 55: 235-8
9. Thompson SJ. Mellon K, Charlton RG. Marsch C. Robinson M, Neal DE. p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br }Urol 1992; 69: 609-13
10. Kallakury BVS. Figge J. Ross JS. Fisher HAG. Figge HL. Jennings TA. Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 1994; 25: 92-7
11. Shurbaji MS. Kalfbleisch JH. Thurmond TS. Immmunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995: 26: 106-9
12. Tannenbaum M. Endometrial tumors and/or associated carcinomas of prostate. Urology 1975; 6: 372-5
13. Dube VE, Farrow GM, Greene LF. Prostatic adenocarcinoma of ductal origin. Cancer 1973: 32: 402-9
14. Gillatt DA. O'Reilly PH. Reeve NL. Endometrioid carcinoma of the prostatic utricle. Br }Urol 1986: 58: 559-60
15. Stavropoulos NE. loackim-Velogianni E. Sidoni K, Stefanou D, Klouvas G. Pavlidis N. Endometrioid carcinoma of the prostate. The diagnostic value of Leu 7 and prostate specific antigen. Br Urol 1993: 71: 309-12
16. Bostwick DG. Dundore PA. Biopsy Pathology of the Prostate. Chapman and Hall Medical. 1997: 167-72
17. Bubendorf L, Sauter G, Moch H et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996: 178: 437-41
18. Feneley MR. Young MPA. Chinyama C, Kirby RS, Parkinson MC. Ki-67 expression in early prostate cancer and associated pathological lesions. J Clin Pathol 1996: 49: 741-8
19. Cueva C. Urdiales F, Nogales F. Varela-Duran J. Papillary endometrioid carcinoma of the prostate. Br Urol 1988: 61: 98-9